These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11727624)

  • 21. A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC).
    Chalfin DB; Teres D; Rapoport J
    Crit Care Med; 2003 Jan; 31(1):306-8. PubMed ID: 12545034
    [No Abstract]   [Full Text] [Related]  

  • 22. Activated protein C alters inflammation and protects renal function in sepsis.
    Keller SA; Moore CC; Evans SL; McKillop IH; Huynh T
    J Surg Res; 2011 Jun; 168(1):e103-9. PubMed ID: 21429520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated protein C: the cure for sepsis - again?
    Hoth T; Evans TW
    Anaesthesia; 2001 Dec; 56(12):1133-5. PubMed ID: 11736767
    [No Abstract]   [Full Text] [Related]  

  • 24. [Activated protein C in severe sepsis--joyful news].
    Møller K; Skinhøj P
    Ugeskr Laeger; 2001 Mar; 163(12):1713. PubMed ID: 11284413
    [No Abstract]   [Full Text] [Related]  

  • 25. Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness.
    Haley M; Cui X; Minneci PC; Deans KJ; Natanson C; Eichacker PQ
    Curr Opin Infect Dis; 2004 Jun; 17(3):205-11. PubMed ID: 15166822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia.
    Schouten M; van 't Veer C; van den Boogaard FE; Gerlitz B; Grinnell BW; Roelofs JJ; Levi M; van der Poll T
    J Infect Dis; 2010 Nov; 202(10):1600-7. PubMed ID: 20925531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human activated protein C: current insights into its mechanism of action.
    Levi M; van der Poll T
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S3. PubMed ID: 18269690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. For sepsis, the drugs don't work.
    Lancet Infect Dis; 2012 Feb; 12(2):89. PubMed ID: 22281132
    [No Abstract]   [Full Text] [Related]  

  • 29. [The FDA's questions].
    Opal S
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():20-2. PubMed ID: 15359935
    [No Abstract]   [Full Text] [Related]  

  • 30. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
    Kalenka A
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698-9; author reply 1699-70. PubMed ID: 15273924
    [No Abstract]   [Full Text] [Related]  

  • 31. [PROWESS: description and key results].
    Vallet B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():12-5. PubMed ID: 15359933
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of heparin and allied compounds in the treatment of sepsis.
    Cornet AD; Smit EG; Beishuizen A; Groeneveld AB
    Thromb Haemost; 2007 Sep; 98(3):579-86. PubMed ID: 17849046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjunctive corticosteroid therapy in pediatric severe sepsis: many unsolved questions.
    Leclerc F; Botte A; Chêne G; Leteurtre S
    Pediatr Crit Care Med; 2011 Jan; 12(1):101-2. PubMed ID: 21209569
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunomodulatory therapy for sepsis: an update.
    Christaki E; Anyfanti P; Opal SM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):1013-33. PubMed ID: 22029521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation].
    Thachil J; Toh CH; Levi M; Watson HG
    Br J Haematol; 2012 May; 157(4):493-4. PubMed ID: 22225506
    [No Abstract]   [Full Text] [Related]  

  • 36. Sepsis and the role of activated protein C.
    Tazbir J
    Crit Care Nurse; 2004 Dec; 24(6):40-5. PubMed ID: 15646088
    [No Abstract]   [Full Text] [Related]  

  • 37. Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.
    Eichacker PQ; Natanson C; Danner RL
    N Engl J Med; 2006 Oct; 355(16):1640-2. PubMed ID: 17050887
    [No Abstract]   [Full Text] [Related]  

  • 38. Recombinant human activated protein C and strict glycemic control in sepsis: mutually exclusive strategies?
    Schultz MJ; Levi M
    Minerva Anestesiol; 2009; 75(7-8):415-6. PubMed ID: 19153552
    [No Abstract]   [Full Text] [Related]  

  • 39. Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C.
    Padkin A; Rowan K; Black N
    BMJ; 2001 Oct; 323(7318):923-6. PubMed ID: 11668142
    [No Abstract]   [Full Text] [Related]  

  • 40. Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C.
    Morris PE; Hite RD; Ohl C
    BioDrugs; 2002; 16(6):403-17. PubMed ID: 12463764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.